TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: Involvement of notch-1 signaling pathway

Cancer Research

Volumn 69, Issue 7, 2009, Pages 2757-2765

  Wang, Zhiwei ^a   Azmi, Asfar Sohail ^a   Ahmad, Aamir ^a   Banerjee, Sanjeev ^a   Wang, Shaomeng ^b   Sarkar, Fazlul H ^a   Mohammad, Ramzi M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA SECRETASE INHIBITOR; JAGGED1; NOTCH1 RECEPTOR; SMALL INTERFERING RNA; TW 37; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; COMPLEMENTARY DNA; MESSENGER RNA; NOTCH1 PROTEIN, HUMAN; PROTEIN BCL 2; SULFONE; TW 37 COMPOUND; TW-37 COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CDC25A GENE; CDK4 GENE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; CYCLIN A GENE; CYCLIN D1 GENE; CYCLIN E GENE; DOWN REGULATION; E2F 1 GENE; FEMALE; GENE; HES 1 GENE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; P27 GENE; P57 GENE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL GROWTH; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOUSE MUTANT; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZAMIDES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA, COMPLEMENTARY; DOWN-REGULATION; FEMALE; HUMANS; MICE; MICE, SCID; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, NOTCH1; RNA, MESSENGER; RNA, SMALL INTERFERING; S PHASE; SIGNAL TRANSDUCTION; SULFONES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66149090396     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3060     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Mortenson MM, Galante JG, Gllad O, et al. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J Cell Biochem 2007;102:1171-1179
3. Huang S, Sinlcrope FA, BH.3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequesterlng Bim and Bak in. human, pancreatic cancer cells. Cancer Res 2008;68:2944-2951.
4. Mohammad RM, Wang S, Banerjee S, Wu X, Chen J, Sarkar l'H. Nonpeptidic small-molecule inhibitor of BcI- 2 and BcI-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas 2005;31:317-324
5. Vaux DL. ABT-737, proving to be a great tool even before it is proven in the clinic. Cell Death Differ 2008;15:807-808
6. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavallable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428
7. Harm CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, In small cell lung cancer. Cancer Res 2008;68:2321-2328
8. Mohammad RM, Goustin AS, Aboukameel A, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-l. Clin Cancer Res 2007;13: 2226-2235
9. Zeitlin BD, Joo E, Dong Z, et al. Antiangiogenic effect of TW37, a small-molecule Inhibitor of Bcl-2. Cancer Res 2006;66:8698-8706
10. Wang Z, Song W, Aboukameel A, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 2008:123: 958-966
11. Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006;49:6139-6142
12. Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Blophys Res Commun 2003;304:437-444
13. Regula KM, Ens K, Kirshenbaum LA. IKKfJ is required for Bcl-2-mediated NF-K B activation in ventricular myocytes. J Biol Chem 2002;277:38676-38682
14. Kumar P, Nlng Y, Polverini PJ. Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhanc- ing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab Invest 2008:88:740-749
15. Tucker CA, Kapanen AI, Chikh G, et al, Silencing Bd- 2 in. models of mantle cell lymphoma is associated with decreases in cyclin Dl, nuclear factor-K'B, p53, bax, and p27 levels. Mol Cancer Ther 2008;7:749-758
16. Anal S, Shiverick K, Medrano T, et al. Downregulation of BCL-2 Induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization. Urology 2007;70:832-837
17. Kaneko T, Zhang Z, Mantellinl MG, et al. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res 2007;67: 9685-9693
18. Miele L. Notch signaling. Clin Cancer Res 2006;12:1074-1079
19. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation, of Notch-1. contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. MoI. Cancer Ther 2006:5:483-493
20. Palomero T1 Domínguez M, Ferrando AA. The role of the PTEN/AKT pathway in NCTTCHl-induced leukemia. Cell Cycle 2008;7:965-970
21. Gutierrez A, Look AT. NOTCH and PI3K-AKT path- ways intertwined. Cancer CeU 2007;12:411-413.
22. Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-KB. Lab Invest 2008:88:11-17
23. All S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA, Sarkar FH. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylm.ethane in vitro and in vivo using an. orthotopic model of pancreatic cancer. MoI. Cancer Ther 2008;7:1708-1719
24. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box Ml transcription factor leads to the inhibition of Invasion and angio- genesis of pancreatic cancer cells. Cancer Res 2007:67: 8293-8300
25. Xu L, Kong D, Zhu L, Zhu W, Andrews DW, Kuo TH. Suppression of IP3-mediated calcium, release and apoptosis by Bcl-2 involves the participation, of protein phosphatase 1. MoI Cell Biochem 2007:295: .153-165
26. Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaUng maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002;8: 979-986
27. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-{K'}B, vascular endothelial growth factor, and matrix metal- loproteinase-9 in pancreatic cancer cells. Cancer Res 2006:66:2778-2784
28. Zhang Y, Banerjee S, Wang Z, et al. Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-KB in. pancreatic cancer. Cancer Res 2006;66: 1025-1032.
29. Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemcitablne treat- ment is dependent on mitochondria-mediated apopto- sis. Int J Cancer 2004;109:182-188
30. Arnold AA, Aboukameel A, Chen J, et al. Preclinical studies of Apogossypolone: a new nonpeptldic pan small-molecule inhibitor of Bcl-2, BcI-XI. and McI-I proteins in follicular smaU cleaved cell lymphoma model. MoI Cancer 2008:7:20.
31. Mohammad RM, Wang S, Aboukameel A, et al. Preclinical, studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bd-X(L) [(-)-gossypol] against diffuse large cell lymphoma MoI Cancer Ther 2005;4: 13-21.
32. Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Inhibition of nudear factor KB activity by genistein is mediated via Notch-I signaling pathway In pancreatic cancer cells. Int J Cancer 2006;118:1930-1936.